Bank Hapoalim BM’s Moderna MRNA Stock Holding History

Bank Hapoalim BM’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-915	Closed	-$232K	–	224
2021 Q4	$232K	Sell	915 -138	-13%	-$40.3K	0.02%	228
2021 Q3	$405K	Sell	1,053 -108	-9%	-$39.8K	0.04%	183
2021 Q2	$273K	Buy	+1,161	New	+$207K	0.03%	216

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank Hapoalim BM's MRNA Position: Q1 2022 in Review

Bank Hapoalim BM sold out of Moderna (MRNA) in Q1 2022, closing a stake of 915 shares — an estimated $232K sold.

Bank Hapoalim BM first reported a position in MRNA in Q2 2021 and held it in 3 quarters. The position peaked at $405K in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

Bank Hapoalim BM reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
Bank Hapoalim BM sold 915 Moderna shares in Q1 2022, an estimated $232K.
Bank Hapoalim BM first reported a position in Moderna in Q2 2021 and held it in 3 quarters.
Bank Hapoalim BM's Moderna position peaked at $405K in Q3 2021.
1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Bank Hapoalim BM's 13F filing for Q1 2022, filed 28 Apr 2022.